

PATENT COOPERATION TREATY

PCT

REC'D 30 JUN 2004

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

WIPO PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 176/61331	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US03/21785	International filing date (day/month/year) 14 July 2003 (14.07.2003)	Priority date (day/month/year) 12 July 2002 (12.07.2002)
International Patent Classification (IPC) or national classification and IPC IPC(7): A61K 31/196, 31/197, 31/198 and US Cl.: 514/561, 562, 567		
Applicant UNIVERSITY OF ROCHESTER		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 63 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 22 January 2004 (22.01.2004)	Date of completion of this report 13 April 2004 (13.04.2004)
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer <i>Phyllis G. Spivack</i> Phyllis G. Spivack Telephone No. 703-308-1235

Form PCT/IPEA/409 (cover sheet)(July 1998)

I. Basis of the report**1. With regard to the elements of the international application:***

- ☒ the international application as originally filed.
- ☒ the description:
pages 1-14 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the claims:
pages 15-19, as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the drawings:
pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☐ the sequence listing part of the description:
pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages none
- ☒ the claims, Nos. none
- ☒ the drawings, sheets/fig none

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>NONE</u>	YES
	Claims <u>1-48</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-48</u>	NO
Industrial Applicability (IA)	Claims <u>1-48</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-48 fail to meet the criteria of PCT Articles 33(2) and 33(3) because the references cited as prior art teach the claimed subject matter. Claims 1-48 lack an inventive step over the prior art. The open language of the present claims does not preclude the addition of any number of additional active agents. The prior art teaches methods of treating various conditions characterized by symptoms that can be alleviated by interfering with the activity of endogenous ligands on the alpha2delta subunit of a voltage-gated calcium channel. Hageman et al., WO 01/85178, and Richardson, WO 96/21437, teach methods for treating such conditions as fatigue, neurodegenerative diseases, tremor disorders, pain or gut disorders comprising administering a composition comprising isoleucine. Gollobin, U.S. Patent 5,789,443, teaches methods for treating hot flashes or symptoms of hormonal variation comprising administering isoleucine. Henry et al., WO 01/68069, teaches methods for treating cough or asthma comprising administering methionine. Bartus et al., US 2002/0058009, teaches the administration of isoleucine to treat migraine, anxiety, psychosis, seizures, attention deficit hyperactivity disorder and a neurodegenerative disorder. Mamer et al., Pharmacology, Biochemistry and Behavior (abstract), teaches the administration of isoleucine to treat chronic pain. Iwato, JP 07025838 (abstract), teaches the administration of isoleucine to treat fatigue. Sonaka et al., EP 689835 (abstract), teaches the administration of isoleucine or methionine to treat inflammatory bowel disease.

Claims 1-48 meet the criteria of PCT Article 33(4) as they are directed to methods of treating a patient for a condition characterized by symptoms that can be alleviated by interfering with the activity of endogenous ligands on the alpha2delta subunit of a voltage-gated calcium channel and compositions therefor.